Fusidic acid cream for impetigo

BMJ

Volumn 324, Issue 7350, 2002, Pages 1394-

  Brown, Erwin M ^a   Wise, Richard ^b   Brown, Nick ^c   Brown, Derek F J ^c   Burrows, Nigel ^c   Sule, Olajumoke ^d   Boswell, Timothy C J ^d   Finch, Roger G ^e   Perkins, William ^d   Weston, Vivienne C ^f   Stoddart, Bethan ^f   Collyns, Timothy ^f   Denton, Miles ^f   Zadik, Paul ^g   Young, Nicola ^g   Owen, Susannah E ^h   Cheesbrough, John S ⁱ   Koning, S ^h   Van Suijlekom Smit, L W A ^h   Nouwen, J L ^h   Verduin, C M ^h   Bernsen, R M D ^h   Oranje, A P ^h   Thomas, S ^j   Van Der Wouden, J C ^j   more..

^a FRENCHAY HOSPITAL   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^e NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^f LEEDS GENERAL INFIRMARY   (United Kingdom)

^g Public Health Laboratory   (United Kingdom)

^h Sheffield Public Health Laboratory ^*  (United Kingdom)

ⁱ ROYAL PRESTON HOSPITAL   (United Kingdom)

^j ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85007696299     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.324.7350.1394/a     Document Type: Letter

References (22)

1. Koning S, van Suijlekom-Smit LWA, Nouwen JL, Verduin CM, Bernsen RMD, Oranje AP, et al. Fusidic acid cream in the treatment of impetigo in general practice: double blind randomised placebo controlled trial. BMJ 2001; 324: 203–206. (26 January.)
2. Andrews J, Ashby J, Jevons G, Marshall T, Lines N, Wise R. A comparison of antimicrobial resistance rates in Gram-positive pathogens isolated in the UK from October 1996 to January 1997 and October 1997 to January 1998. J Antimicrob Chemother 2000; 45: 285–293.
3. Brown EM, Thomas P. Fusidic acid resistance in Staphylococcus aureus isolates. Lancet 2002; 359 (in press).
4. Koning S, van Suijlekom-Smit LWA, Nouwen JL, Verduin CM, Bernsen RMD, Oranje AP, et al. Fusidic acid cream in the treatment of impetigo in general practice: double blind randomised placebo controlled trial. BMJ 2001; 324: 203–206. (26 January.)
5. Speller DCE, Johnson AP, James D, Marples RR, Charlett A, George RC. Resistance to methicillin and other antibiotics in isolates of Staphylococcus aureus from blood and cerebrospinal fluid, England and Wales, 1989-95. Lancet 1997; 350: 323–325.
6. Andrews J, Ashby J, Jevons G, Marshall T, Lines N, Wise R. A comparison of antimicrobial resistance rates in Gram-positive pathogens isolated in the UK from October 1996 to January 1997 and October 1997 to January 1998. J Antimicrob Chemother 2000; 45: 285–293.
7. Ravenscroft JC, Layton A, Barnham M. Observations on high levels of fusidic acid resistant Staphylococcus aureus in Harrogate, North Yorkshire, UK. Clin Exper Dermatol 2000; 25: 327–330.
8. Andrews J, for the BSAC Working Party on Susceptibility Testing. BSAC standardized disc susceptibility testing method. J Antimicrob Chemother 2001; 48(suppl S1): 43–57.
9. Koning S, van Suijlekom-Smit LWA, Nouwen JL, Verduin CM, Bernsen RMD, Oranje AP, et al. Fusidic acid cream in the treatment of impetigo in general practice: double blind randomised placebo controlled trial. BMJ 2001; 324: 203–206. (26 January.)
10. Koning S, van Suijlekom-Smit LWA, Nouwen JL, Verduin CM, Bernsen RMD, Oranje AP, et al. Fusidic acid cream in the treatment of impetigo in general practice: double blind randomised placebo controlled trial. BMJ 2001; 324: 203–206. (26 January.)
11. Turnidge J, Collignon P. Resistance to fusidic acid. Int J Antimicrob Agents 1999; 12(suppl 2): S35–S44.
12. Lowbury EJL, Cason JS, Jackson D, Miller RWS. Fucidin for staphyloccocal infection of burns. Lancet 1962; 2: 478–480.
13. Ravenscroft JC, Layton A, Barnham M. Observations on high levels of fusidic acid resistant Staphylococcus aureus in Harrogate, North Yorkshire, UK. Clin Exper Dermatol 2000; 25: 327–330.
14. Koning S, van Suijlekom-Smit LWA, Nouwen JL, Verduin CM, Bernsen RMD, Oranje AP, et al. Fusidic acid cream in the treatment of impetigo in general practice: double blind randomised placebo controlled trial. BMJ 2001; 324: 203–206. (26 January.)
15. Hilson GRF. In-vitro studies of a new antibiotic (Fucidin). Lancet 1962; 1: 932–933.
16. Lowbury EJL, Cason JS, Jackson DM, Miller RWS. Fucidin for staphylococcal infection of burns. Lancet 1962; 2: 478–480.
17. Koning S, van Suijlekom-Smit LWA, Nouwen JL, Verduin CM, Bernsen RMD, Oranje AP, et al. Fusidic acid cream in the treatment of impetigo in general practice: double blind randomised placebo controlled trial. BMJ 2001; 324: 203–206. (26 January.)
18. Cars O, Möllstad S, Melander A. Variation in antibiotic use in the European Union. Lancet 2001; 357: 1851–1853.
19. De Neeling AJ, van Leeuwen WJ, Schouls LM, Scot CS, van Veen-Rutgers A, Beunders A, et al. Reistance of staphylococci in the Netherlands: surveillance by an electronic network during 1989-1995. J Antimicrob Chemother 1998; 41: 93–101.
20. Cars O, Möllstad S, Melander A. Variation in antibiotic use in the European Union. Lancet 2001; 357: 1851–1853.
21. De Neeling AJ, van Leeuwen WJ, Schouls LM, Schot CS, van Veen-Rutgers A, Beunders AJ, et al. Resistance of staphylococci in the Netherlands: surveillance by an electronic network during 1989-1995. J Antimicrob Chemother 1998; 41: 93–101.
22. Brown EM, Thomas P. Fusidic acid resistance in Staphylococcus aureus isolates. Lancet 2002; 359: 803.